Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 18/20 | 0.52 |
| ▸ | F2 | P00734 | 12/20 | 0.52 |
| ▸ | F10 | P00742 | 12/20 | 0.52 |
| ▸ | F3 | P13726 | 11/20 | 0.52 |
| ▸ | F11 | P03951 | 8/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | KCNB1 | Q14721 | 2/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2536503 | 0.95 | F7 (0.56) | F7F2F10F3F11 | |
| Trifluoroacetic Acid SCHEMBL2539624 | 0.92 | F7 (0.54) | F7F2F10F3F11 | |
| Trifluoroacetic Acid SCHEMBL2538019 | 0.91 | F2 (0.59) | F7F2F10F3F11 | |
| Trifluoroacetic Acid SCHEMBL4657077 | 0.90 | F7 (0.53) | F7F2F10F3F11 | |
| Trifluoroacetic Acid SCHEMBL2539699 | 0.87 | F7 (0.50) | F7F2F10F3F11 | |
| SCHEMBL2537015 | 0.86 | F7 (0.59) | F7F2F10F3F11 | |
| Trifluoroacetic Acid SCHEMBL2545509 | 0.86 | F7 (0.55) | F7F2F10F3F11 | |
| SCHEMBL2536769 | 0.86 | F7 (0.64) | F7F2F10F3F11 | |
| Trifluoroacetic Acid SCHEMBL2542719 | 0.85 | F7 (0.72) | F7F2F10F3F11 | |
| Trifluoroacetic Acid SCHEMBL4655945 | 0.82 | F7 (0.47) | F7F2F10F3F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996541-B1 | 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8044242-B2 | 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090131473-A1 | 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131473-A1 | 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F7, F9, F12 | F7 1/4885F2 7/4885F10 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.